I. Diagnosis and classification of obesity Karl Nadolsky presented a panel discussion on “Anthropometric and clinical components to the diagnosis: Nadolsky pointed out that, unlike other guidelines that are “BMI-centric,” the 2016 obesity guidelines have a different diagnostic model. “The 2016 obesity guidelines continue the “obesity-related complication-centered” model proposed by the 2014 obesity consensus, screening for obesity-related complications and evaluating their severity, supplemented by anthropometric indicators for obesity classification1,2 , which is more useful for clinical measures. Practical guidance significance. 1, “anthropometric indicators + clinical indicators” of the diagnosis and grading mode 2, BMI is not the only anthropometric indicators Karl Nadolsky pointed out that, at present, the international only BMI as overweight or obesity diagnosis standards is not perfect. Waist circumference should also be used as a screening indicator, especially in the population with BMI <35kg/m2. 2014 obesity consensus2 adopts the data of IDF, American male waist circumference ≥102cm, female waist circumference ≥88cm can be used as abdominal obesity cut point, South Asians are suitable to male waist circumference ≥90cm, female waist circumference ≥80cm as abdominal obesity cut point. 2016 obesity guideline1 is widely collected including IDF, WHO, including seven obesity-related institutions data, the abdominal obesity cut point of 12 different races to summarize, and especially pointed out that Southeast Asia, South Asia, East Asia is appropriate to male waist circumference ≥ 85cm, female waist circumference ≥ 74-80cm as abdominal obesity cut point, more strict than the division of 2014 obesity consensus. Second, "complication-centered" treatment model W. Timothy Garvey pointed out in the 2016 AACE conference that obesity is a complex chronic disease, the goal of obesity treatment should be to control the complications of obesity and obesity itself, whether there are complications, the severity of complications will become the classification of obese patients' disease Assessment, treatment mode selection and weight reduction treatment efficacy evaluation of the primary consideration factors, rather than simply to reduce BMI as the goal. 1.Treatment target The 2016 obesity guideline1 continues the view of obesity tertiary prevention of the 2014 obesity consensus, and the treatment target of obesity complications in tertiary prevention has been refined and classified, and the weight reduction target has been clearly quantified, as follows: 2.Pharmacological treatment When the 2014 obesity consensus was released, the FDA only approved three kinds of weight loss drugs that could be used for a long time, and because of the low evidence-based evidence, the guideline did not recommend the use of drugs. When the 2016 obesity guidelines were released, the FDA approved a total of five kinds of long-term use of weight loss drugs, so AACE made individualized drug recommendations for obese patients with 17 types of diseases including chronic kidney disease, hypertension and epilepsy.1 This is of greater significance for the clinical use of drugs. 3, surgery treatment 2014 obesity consensus2 recommended that patients with BMI ≥ 40 kg/m2 or BMI in 35 kg/m2 ~ 39.9 kg/m2 and combined with serious obesity-related complications can consider weight loss surgery. 2016 obesity guideline1 recommendation is not limited to this, it is recommended that patients whose quality of life is greatly affected and BMI in 30 kg/m2 ~ 34.5 kg/m2 combined with Bariatric surgery may be considered in patients with diabetes or metabolic syndrome.